Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agile Therapeutics (AGRX)
OTHER OTC:AGRX
RESEARCH TOOLSreports
Agile Therapeutics (AGRX) Stock Price & Analysis
1,498 Followers
AGRX Stock Chart & Stats
Day’s Range$0.37 - $0.4
52-Week Range― - ―
Previous Close$0.39
Volume59.38K
Average Volume (3M)N/A
Market Cap
$2.61M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 09, 2024EPS Estimate
-$0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Agile Therapeutics News
Bulls Say, Bears Say
Bulls Say
Market ExclusivityTwirla has no therapeutic equivalents which should require all PBMs to cover and reimburse Twirla without cost sharing, improving access to the product.
Regulatory UpdateThe updated guidance may impact and improve contraception access for 49M women.
Sales Growth ForecastAgile is on pace to becoming profitable with a forecast of 70% year-over-year sales growth from the existing strategy.
Bears Say
Capital Raise ConcernsAgile may require a significantly dilutive equity capital raise as soon as the beginning of 2Q24.
Financial PerformancePreliminary full-year 2023 revenue guidance of $20M–$21M below prior guidance of ≥$25M, implying a decline in 4Q23 revenue.
Regulatory UncertaintyUncertainty regarding the timing of the impact from updated FAQs requiring contraceptives to be covered without co-pays, which may not benefit the company until 2025.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AGRX FAQ
What was Agile Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Agile Therapeutics’s market cap?
Currently, no data Available
When is Agile Therapeutics’s upcoming earnings report date?
Agile Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 15 days.
How were Agile Therapeutics’s earnings last quarter?
Agile Therapeutics released its earnings results on Mar 28, 2024. The company reported -$1.46 earnings per share for the quarter, missing the consensus estimate of -$0.92 by -$0.54.
Is Agile Therapeutics overvalued?
According to Wall Street analysts Agile Therapeutics’s price is currently Overvalued.
Does Agile Therapeutics pay dividends?
Agile Therapeutics does not currently pay dividends.
What is Agile Therapeutics’s EPS estimate?
Agile Therapeutics’s EPS estimate is -$0.48.
How many shares outstanding does Agile Therapeutics have?
Currently, no data Available
What happened to Agile Therapeutics’s price movement after its last earnings report?
Agile Therapeutics reported an EPS of -$1.46 in its last earnings report, missing expectations of -$0.92. Following the earnings report the stock price went down -8.108%.
Which hedge fund is a major shareholder of Agile Therapeutics?
Among the largest hedge funds holding Agile Therapeutics’s share is Perceptive Advisors LLC. It holds Agile Therapeutics’s shares valued at N/A.
---
Agile Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 10.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.99%
Trailing 12-Months
Company Description
Agile Therapeutics
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
---
AGRX Company Deck
---
AGRX Earnings Call
Q4 2024
0:00 / 0:00
---
AGRX Stock 12 Months Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering AGRX
1 Year
1 Year Success Rate
8/26 ratings generated profit
1 Year Average Return
-6.14%
reiterated a buy rating 10 months ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -6.14% per trade.
---